Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
Blog - Melanoma360
02/05/2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
|
|
02/05/2021
“A Celebration of Friendship” Solo Exhibit Shares Heartfelt Story While Raising Funds for AIM at Melanoma Foundation
Contact: Chris Miller (972) 788-2599 Publicity cjmiller@rainmakeradv.com (RICHARDSON, TEXAS) How do we honor the meaning of friendship and the potential…
|
|
02/05/2021
Survivor Spotlight: Mark Lewis, Stage III Melanoma Survivor
A Partner Through It All By Mara Klecker Mark Lewis was less than a year into his relationship when he…
|
02/05/2021
Art Exhibit to Honor a Friendship and Raise Funds for AIM
By Mara Klecker Melanie Brannan has had difficulty falling asleep in recent weeks. Throughout the day and into the night,…
|
|
01/26/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
January 24, 2021 19:07 ET | Source: Junshi Biosciences Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
|
|
01/10/2021
In Plain English—Intratumoral Injection: Boosting the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses
By Kim Margolin, M.D. Using the patient’s own immune system to combat melanoma is a powerful tool for patients…
|
01/08/2021
President’s Letter | January 2021
From the Desk of Samantha Guild In a January newsletter it is traditional to wish you a happy new year…
|
01/08/2021
Why Is the Tissue Bank So Important For Melanoma Research?
We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment;…
|
01/08/2021
What is Oral Parity, and Why Does it Matter?
We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
|
01/08/2021
AIM Launches a New Program That Addresses the Emotional Needs of Melanoma Patients
by Mara Klecker Amid the COVID-19 pandemic, AIM at Melanoma has redoubled its efforts to meet the needs of melanoma…
Recent Posts
Nov. 05, 2024
Crafting Hope: Chris Krizek’s Journey from Cancer Patient to AIM Fundraiser with Wine Cork Creations
Nov. 04, 2024
Book Suggestions for Caregivers
Oct. 28, 2024
Turn Hope into Action with AIM at Melanoma
Oct. 17, 2024
In Plain English: Update on Melanoma Vaccines, 2024
Oct. 15, 2024